Health
CARB-X funds Phico to develop new intravenous engineered bacteriophage drug – The Pharma Letter
Global non-profit partnership CARB-X is funding privately-held UK company Phico Therapeutics to develop a new intravenous engineered bacteriophage drug to treat
Global non-profit partnership CARB-X is funding privately-held UK company Phico Therapeutics to develop…To continue reading The Pharma Letter please login, subscribe or claim a 7 day free trial subscription and access exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space.
Or, if you’re only interested in reading the content about a specific topic (M&A, coronavirus/COVID-19, pricing, reimbursement and access, outsourcing, CRO…
-
General8 hours agoGymnastics club in Berwick shuts down following child safety complaint
-
Noosa News23 hours agoSeven key takeaways from the Queensland probe’s first week
-
General23 hours agoKhawaja causes chaos, Starc and Stokes star as batters collapse — five quick hits from Ashes first Test day one
-
General14 hours agoCritically endangered orchid thrives as NSW Mid North Coast cemetery provides habitat refuge